Risk factors for parvovirus B19 infection in pregnancy

JAMA

Volumn 281, Issue 12, 1999, Pages 1099-1105

  Valeur Jensen, Anne Kristine ^a   Pedersen, Carsten B ^a   Westergaard, Tine ^a   Jensen, Inge P ^b   Lebech, Morten ^b   Andersen, Per K ^a   Aaby, Peter ^a   Pedersen, Bent Nørgaard ^b   Melbye, Mads ^a,b  

^a DEPARTMENT OF EPIDEMIOLOGY RESEARCH   (Denmark)

^b STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DENMARK; ENDEMIC DISEASE; EPIDEMIC; FEMALE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; NEWBORN INFECTION; NURSERY SCHOOL; OCCUPATIONAL HAZARD; PARVOVIRUS; POPULATION RISK; PREGNANCY; PRIORITY JOURNAL; SEROCONVERSION; TEACHER; VIRUS INFECTION;

EID: 0033620377     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.12.1099     Document Type: Article

References (32)

1. Anderson MJ, Jones SE, Fisher-Hoch SP, et al. Human parvovirus, the cause of erythema infectiosum (fifth disease)? [letter]. Lancet 1983;1:1378.
2. Brown KE, Young NS. Parvovirus B19 in human disease. Annu Rev Med. 1997;48:59-67.
3. Cohen B. Parvovirus 819: an expanding spectrum of disease. BMJ. 1995;311:1549-1552.
4. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TMS. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet. 1984;2:1033-1034.
5. Public Health Laboratory Service Working Party on Fifth Disease. Prospective study of human parvovirus (B19) infection in pregnancy. BMJ. 1990;300:1166-1170.
6. Torok TJ. Parvovirus B19 and human disease. Adv Intern Med 1992;37:431-455.
7. Cohen BJ, Hall SM, Healing TD, Morse DL, Owen RJ. Quarterly communicable disease review January to March 1993 from the PHLS Communicable Disease Surveillance Centre. J Public Health Med. 1993; 15:281-288.
8. Woolf AD, Campion GV, Chishick A, et al. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149:1153-1156.
9. Rice PS, Cohen BJ. A school outbreak of parvovirus B19 infection investigated using salivary antibody assays. Epidemiol Infect. 1996;116:331-338.
10. Chorba T, Coccia P, Holman RC, et al. The role of parvovirus B19 in aplastic crisis and erythema infectiosum (fifth disease). J Infect Dis. 1986;154:383-393.
11. Gillespie SM, Cartter ML, Asch S, et al. Occupational risk of human parvovirus B19 infection for school and day-care personnel during an outbreak of erythema infectiosum. JAMA. 1990;263:2061-2065.
12. Cartter ML, Farley TA, Rosengren S, et al. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis. 1991;163:282-285
13. Westergaard T, Andersen PK, Pedersen JB, et al. Birth characteristics, sibling patterns, and acute leukemia risk in childhood: a population-based cohort study. J Natl Cancer Inst. 1997;89:939-947.
14. Statistics Denmark. Statistics on Persons: A Register-Based Statistical System. Copenhagen, Denmark: Statistics Denmark; 1995.
15. Melbye M, Wohlfart J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 1997;336:81-85.
16. Knudsen LB, Kristensen FB. Monitoring perinatal mortality and perinatal care with a national register: content and usage of the Danish Medical Birth Register. Community Med. 1986;8:29-36.
17. Becker NG, Melbye M. Use of a log-linear model to compute the empirical survival curve from interval-censored data, with application to data on HIV tests for HIV positivity. Aust J Stat. 1991;33:125-133.
18. Carstensen B. Regression models for interval censored survival data: application to HIV infection in Danish homosexual men. Stat Med. 1996;15:2177-2189.
19. Agresti A. Categorical Data Analysis. New York, NY: John Wiley & Sons Inc; 1990.
20. SAS Institute Inc. The GENMOD procedure. In: SAS/STA T Software: Changes and Enhancements for Release 6.12. Cary, NC: SAS Institute Inc; 1996: 21-42.
21. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol. 1985;122:904-914.
22. Anderson U, Tsou C, Parker RA, et al. Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assay. J Clin Microbiol. 1986;24:522-526.
23. Eis-Hubinger AM, Oldenburg J, Brackmann HH, Matz B, Schneweis KE. The prevalence of antibody to parvovirus B19 in hemophiliacs and in the general population. Zentralbl Bakteriol. 1996;284:232-240.
24. Cohen BJ, Buckley MM. The prevalence of antibody to human parvovirus 819 in England and Wales. J Med Microbiol. 1988;25:151-153.
25. Pillay D, Patou G, Hurt S, Kibbler CC, Griffiths PD. Parvovirus B19 outbreak in a children's ward. Lancet. 1992;339:107-109.
26. Bell LM, Naides SJ, Stoffman P, Hodinka RL, Plotkin SA. Human parvovirus B19 infection among hospital staff members after contact with infected patients. N Engl J Med. 1989;321:485-491.
27. Azzi A, Trotta M, Zakrzewska K, et al. Human parvovirus B19 infection within a family and risk for pregnant women. Epidemiol Infect. 1996;117:401-403.
28. Harger JH, Adler SP, Koch WC, Harger GF. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol. 1998;91:413-420.
29. Koch WC, Adler SP. Human parvovirus B19 infections in women of childbearing age and within families. Pediatr Infect Dis J. 1989;8:83-87.
30. Gratacos E, Torres P, Vidal J, et al. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis. 1995; 171:1360-1363.
31. Skjoldebrand-Sparre L, Fridell E, Nyman M, Wahren B. A prospective study of antibodies against parvovirus B19 in pregnancy. Acta Obstet Gynecol Scand 1996;75:336-339.
32. Rodis JF, Quinn DL, Gary GWJ, et al. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol. 1990;163:1168-1171.